Investigating how metabolic changes affect treatment response in a specific type of ovarian cancer
Metabolic and epigenetic reprogramming in cyclin E high ovarian cancer
This study is looking at how changes in a substance called acetyl-CoA affect the behavior of ovarian cancer cells, especially how they repair their DNA and respond to certain treatments, with the goal of finding better ways to help patients with this tough type of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-11073067 on NIH RePORTER |
What this research studies
This research focuses on understanding how changes in metabolism, specifically involving acetyl-CoA, influence the behavior of high cyclin E ovarian cancer cells. The study aims to explore how these metabolic alterations affect DNA repair mechanisms and the cancer's response to therapies, particularly PARP inhibitors. By examining the relationship between acetyl-CoA levels and histone modifications, researchers hope to identify new treatment strategies that could improve outcomes for patients with this aggressive cancer type.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with high grade serous ovarian cancer exhibiting high levels of cyclin E expression.
Not a fit: Patients with low cyclin E expression or those with other types of ovarian cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with high cyclin E ovarian cancer, particularly those resistant to current therapies.
How similar studies have performed: Previous research has shown promising results in targeting metabolic pathways in cancer treatment, suggesting that this approach could be beneficial.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Aird, Katherine Marie — University of Pittsburgh at Pittsburgh
- Study coordinator: Aird, Katherine Marie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.